Literature DB >> 11472257

Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents.

K Augustyns1, K Amssoms, A Yamani, P K Rajan, A Haemers.   

Abstract

Trypanothione is the key molecule in the defence mechanism of Trypanosoma and Leishmania against oxidative stress. The uniqueness of trypanothione makes the metabolism of this molecule an attractive target in antitrypanosomal and antileishmanial drug design. It became clear that this antioxidant cascade can be considered as the "Achilles heel" of these parasites. The following targets and their respective inhibitors will be discussed: biosynthesis of trypanothione with glutathionylspermidine synthetase and trypanothione synthetase; biosynthesis of glutathione with gamma-glutamylcysteine synthetase; biosynthesis of spermidine with ornithine decarboxylase; trypanothione hydroperoxide metabolism with tryparedoxine peroxidase, tryparedoxine and trypanothione reductase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472257     DOI: 10.2174/1381612013397564

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

Review 1.  Parasite-specific trypanothione reductase as a drug target molecule.

Authors:  R Luise Krauth-Siegel; Oliver Inhoff
Journal:  Parasitol Res       Date:  2003-04-23       Impact factor: 2.289

2.  Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.

Authors:  Georgina A Holloway; William N Charman; Alan H Fairlamb; Reto Brun; Marcel Kaiser; Edmund Kostewicz; Patrizia M Novello; John P Parisot; John Richardson; Ian P Street; Keith G Watson; Jonathan B Baell
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

3.  Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives.

Authors:  Christophe Dardonville; Cristina Fernández-Fernández; Sarah-Louise Gibbons; Nadine Jagerovic; Lidia Nieto; Gary Ryan; Marcel Kaiser; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Putrescine analogue cytotoxicity against Trypanosoma cruzi.

Authors:  D Menezes; C Valentim; M F Oliveira; M A Vannier-Santos
Journal:  Parasitol Res       Date:  2005-11-11       Impact factor: 2.289

5.  Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design.

Authors:  Ahilan Saravanamuthu; Tim J Vickers; Charles S Bond; Mark R Peterson; William N Hunter; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

6.  Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione.

Authors:  Siucheong Yan; Fei Li; Keyang Ding; Hongzhe Sun
Journal:  J Biol Inorg Chem       Date:  2003-06-21       Impact factor: 3.358

7.  Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis.

Authors:  Leah S Torrie; Susan Wyllie; Daniel Spinks; Sandra L Oza; Stephen Thompson; Justin R Harrison; Ian H Gilbert; Paul G Wyatt; Alan H Fairlamb; Julie A Frearson
Journal:  J Biol Chem       Date:  2009-10-14       Impact factor: 5.157

8.  Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi.

Authors:  Deuan C Jones; Antonio Ariza; Wing-Huen A Chow; Sandra L Oza; Alan H Fairlamb
Journal:  Mol Biochem Parasitol       Date:  2009-09-10       Impact factor: 1.759

9.  Investigation of trypanothione reductase as a drug target in Trypanosoma brucei.

Authors:  Daniel Spinks; Emma J Shanks; Laura A T Cleghorn; Stuart McElroy; Deuan Jones; Daniel James; Alan H Fairlamb; Julie A Frearson; Paul G Wyatt; Ian H Gilbert
Journal:  ChemMedChem       Date:  2009-12       Impact factor: 3.466

10.  Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase.

Authors:  Stephen Patterson; Deuan C Jones; Emma J Shanks; Julie A Frearson; Ian H Gilbert; Paul G Wyatt; Alan H Fairlamb
Journal:  ChemMedChem       Date:  2009-08       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.